Saturday 17 October 2026
Export ARDX’s income statement to Excel — free account
Ardelyx, Inc.
ARDX Healthcare Biotechnology
Ardelyx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $407.3 million, up 22.1% from fiscal 2024. In the quarter to June 2026, revenue grew 23.8%, EPS grew 12.5%, free cash flow grew 75.3% and total debt rose 25.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
3.09
0.18
−5.50%
Follow ARDX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 3 | 2 | 5 |
+8 more TTM periods Free account |
| (38.61%) | (39.46%) | (36.21%) | (36.18%) | ||
| (10.68%) | (12.69%) | (13.14%) | (13.24%) | ||
ROIC |
(18.62%) | (20.50%) | (24.37%) | (20.86%) | |
Return on Tangible Assets |
(17.88%) | (21.17%) | (20.82%) | (19.73%) | |
Average Days of Receivables |
81.24 | 70.70 | 64.38 | 70.22 | |
Free Cash Flow per Share |
(0.07) | (0.15) | (0.18) | (0.23) | |
Free Cash Flow |
(17.92) | (37.50) | (43.97) | (55.35) | |
Capital Expenditures |
(0.60) | (1.24) | (1.49) | (1.72) | |
| Other line items | |||||
Cash ROIC |
(2.62%) | (6.35%) | (6.93%) | (9.24%) | |
Accounts Receivable Turnover |
5.54 | 6.61 | 6.29 | 6.14 | |
Accounts Payable Turnover |
0.85 | 1.53 | 2.24 | 2.74 | |
Inventory Turnover |
1.06 | 1.38 | 2.03 | 2.57 | |
Average Days of Payables |
551.93 | 321.15 | 177.57 | 142.96 | |
Days of Inventory on Hand |
371.57 | 259.07 | 163.73 | 195.68 | |
Tax Rate |
0.00 | 0.00 | 0.02 | 0.02 | |
Research and Development Expense of Revenue |
19.34% | 17.95% | 17.56% | 15.65% | |
Selling, General and Administrative Expense of Revenue |
82.89% | 83.31% | 82.79% | 82.09% | |
Share Based Compensation of Revenue |
12.12% | 11.93% | 12.02% | 11.65% | |
Interest Coverage |
(1.24) | (1.29) | (1.44) | (1.42) | |
Operating CF/Net income |
0.31 | 0.62 | 0.69 | 0.95 | |
Depreciation/Fixed assets |
1.88 | 1.68 | 1.40 | 1.28 | |
Capex/Depreciation |
(0.18) | (0.37) | (0.49) | (0.65) | |
Revenue per Share |
1.82 | 1.74 | 1.69 | 1.65 | |
Operating CF per Share |
(0.07) | (0.15) | (0.18) | (0.22) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates